These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
265 related articles for article (PubMed ID: 22406638)
1. Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. Gershenson DM; Sun CC; Iyer RB; Malpica AL; Kavanagh JJ; Bodurka DC; Schmeler K; Deavers M Gynecol Oncol; 2012 Jun; 125(3):661-6. PubMed ID: 22406638 [TBL] [Abstract][Full Text] [Related]
2. PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. Tang M; O'Connell RL; Amant F; Beale P; McNally O; Sjoquist KM; Grant P; Davis A; Sykes P; Mileshkin L; Moujaber T; Kennedy CJ; deFazio A; Tan K; Antill Y; Goh J; Bonaventura T; Scurry J; Friedlander M Gynecol Oncol; 2019 Sep; 154(3):531-538. PubMed ID: 31227223 [TBL] [Abstract][Full Text] [Related]
3. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839 [TBL] [Abstract][Full Text] [Related]
4. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma. Llaurado Fernandez M; Dawson A; Kim H; Lam N; Russell H; Bruce M; Bittner M; Hoenisch J; Scott SA; Talhouk A; Chiu D; Provencher D; Nourmoussavi M; DiMattia G; Lee CH; Gilks CB; Köbel M; Carey MS Gynecol Oncol; 2020 Apr; 157(1):12-20. PubMed ID: 31954537 [TBL] [Abstract][Full Text] [Related]
5. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Cobb LP; Sun CC; Iyer R; Nick AM; Fleming ND; Westin SN; Sood AK; Wong KK; Silva EG; Gershenson DM Gynecol Oncol; 2020 Sep; 158(3):653-658. PubMed ID: 32709538 [TBL] [Abstract][Full Text] [Related]
7. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. Grisham RN; Iyer G; Sala E; Zhou Q; Iasonos A; DeLair D; Hyman DM; Aghajanian C Int J Gynecol Cancer; 2014 Jul; 24(6):1010-4. PubMed ID: 24978709 [TBL] [Abstract][Full Text] [Related]
8. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube. Noguera IR; Sun CC; Broaddus RR; Branham D; Levenback CF; Ramirez PT; Sood AK; Coleman RL; Gershenson DM Gynecol Oncol; 2012 Jun; 125(3):640-5. PubMed ID: 22387451 [TBL] [Abstract][Full Text] [Related]
9. Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors. Gershenson DM; Cobb LP; Sun CC Gynecol Oncol; 2020 Dec; 159(3):601-603. PubMed ID: 33019983 [No Abstract] [Full Text] [Related]
10. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Schmeler KM; Sun CC; Bodurka DC; Deavers MT; Malpica A; Coleman RL; Ramirez PT; Gershenson DM Gynecol Oncol; 2008 Mar; 108(3):510-4. PubMed ID: 18155273 [TBL] [Abstract][Full Text] [Related]
11. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470 [TBL] [Abstract][Full Text] [Related]
12. Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer. Andres S; Finch L; Iasonos A; Zhou Q; Girshman J; Chhetri-Long R; Green H; Jang D; O'Cearbhaill R; Kyi C; Cohen S; Friedman C; Makker V; Chi DS; Sonoda Y; Chiang S; Aghajanian C; Weigelt B; Grisham RN Gynecol Oncol; 2024 Oct; 189():30-36. PubMed ID: 38991472 [TBL] [Abstract][Full Text] [Related]
13. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial. Gershenson DM; Miller A; Brady WE; Paul J; Carty K; Rodgers W; Millan D; Coleman RL; Moore KN; Banerjee S; Connolly K; Secord AA; O'Malley DM; Dorigo O; Gaillard S; Gabra H; Slomovitz B; Hanjani P; Farley J; Churchman M; Ewing A; Hollis RL; Herrington CS; Huang HQ; Wenzel L; Gourley C Lancet; 2022 Feb; 399(10324):541-553. PubMed ID: 35123694 [TBL] [Abstract][Full Text] [Related]
14. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. Monk BJ; Grisham RN; Banerjee S; Kalbacher E; Mirza MR; Romero I; Vuylsteke P; Coleman RL; Hilpert F; Oza AM; Westermann A; Oehler MK; Pignata S; Aghajanian C; Colombo N; Drill E; Cibula D; Moore KN; Christy-Bittel J; Del Campo JM; Berger R; Marth C; Sehouli J; O'Malley DM; Churruca C; Boyd AP; Kristensen G; Clamp A; Ray-Coquard I; Vergote I J Clin Oncol; 2020 Nov; 38(32):3753-3762. PubMed ID: 32822286 [TBL] [Abstract][Full Text] [Related]
15. Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors. Stanley B; Hollis RL; Nunes H; Towler JD; Yan X; Rye T; Dawson C; Mackean MJ; Nussey F; Churchman M; Herrington CS; Gourley C Gynecol Oncol; 2019 Feb; 152(2):278-285. PubMed ID: 30501904 [TBL] [Abstract][Full Text] [Related]
16. Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience. Dalton HJ; Fleming ND; Sun CC; Bhosale P; Schmeler KM; Gershenson DM Gynecol Oncol; 2017 Apr; 145(1):37-40. PubMed ID: 28139261 [TBL] [Abstract][Full Text] [Related]
17. Quantification of ER/PR expression in ovarian low-grade serous carcinoma. Escobar J; Klimowicz AC; Dean M; Chu P; Nation JG; Nelson GS; Ghatage P; Kalloger SE; Köbel M Gynecol Oncol; 2013 Feb; 128(2):371-6. PubMed ID: 23103384 [TBL] [Abstract][Full Text] [Related]
18. The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer. Chen S; Dai X; Gao Y; Shen F; Ding J; Chen Q Sci Rep; 2017 Dec; 7(1):16922. PubMed ID: 29208958 [TBL] [Abstract][Full Text] [Related]
19. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Crispens MA; Bodurka D; Deavers M; Lu K; Silva EG; Gershenson DM Obstet Gynecol; 2002 Jan; 99(1):3-10. PubMed ID: 11777502 [TBL] [Abstract][Full Text] [Related]
20. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience. Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]